Table 1 Comparison of baseline characteristics between patients with high and low TOP2A protein expression
From: The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer
| Â | All patients | TOP2A protein expression | ||
|---|---|---|---|---|
| Â | High | Low | P value | |
n = 434 (100%) | n = 127 (29.3%) | n = 307 (70.7%) |  | |
Median age (range) a | 45(26–80) | 45(26–80) | 45(26–80) | 0.869 |
Age at surgery (yr) | Â | Â | Â | 0.725 |
  ≤ 40 | 124(28.6) | 37 (29.1) | 87 (28.3) |  |
  > 40,< 60 | 288 (66.3) | 82 (64.6) | 206 (67.1) |  |
  > =65 | 22 (5.1) | 8 (6.3) | 14 (4.6) |  |
Menopausal status | Â | Â | Â | 1.000 |
 Premenopausal | 323 (74.4) | 95 (74.8) | 228 (74.3) |  |
 Postmenopausal | 111 (25.6) | 32 (25.2) | 79 (25.7) |  |
Breast surgery | Â | Â | Â | 0.847 |
 Lumpectomy | 35 (8.1) | 11 (8.7) | 24 (7.8) |  |
 Mastectomy | 399 (91.9) | 116 (91.3) | 283 (92.2) |  |
Pathologic tumor size (mm) | Â | Â | Â | 0.244 |
  ≤ 20 | 176 (40.5) | 57 (44.9) | 119 (38.8) |  |
 21–50 | 249 (57.4) | 69 (54.3) | 180 (58.6) |  |
  > 50 | 9 (2.1) | 1 (0.8) | 8 (2.6) |  |
Number of involved lymph nodes | Â | Â | Â | 0.920 |
 0 | 291 (67.1) | 87 (68.5) | 204 (66.5) |  |
 1 | 77 (17.7) | 22 (17.3) | 55 (17.9) |  |
 2 | 33 (7.6) | 10 (7.9) | 23 (7.5) |  |
 3 | 33 (7.6) | 8 (6.3) | 25 (8.1) |  |
Predominant histologic subtype | Â | Â | Â | 0.765 |
 Ductal | 407 (93.8) | 118(92.9) | 289(94.1) |  |
 Lobular | 13 (3.0) | 5 (3.9) | 8 (2.6) |  |
 Other | 14 (3.2) | 4 (3.2) | 10 (3.3) |  |
Grade | Â | Â | Â | 0.028 |
 1–2 | 304 (70.0) | 79 (62.2) | 225 (73.3) |  |
 3 | 130 (30.0) | 48 (37.8) | 82 (26.7) |  |
Median Ki67 (range)b | 10(2–90) | 20(5–90) | 10 (2–80) | 0.018 |
Ki67 | Â | Â | Â | 0.119 |
  < 14% | 220 (50.7) | 59 (46.5) | 161 (52.4) |  |
  ≥ 14%, < 20% | 14 (3.2) | 4 (3.1) | 10 (3.3) |  |
  ≥ 20%,< 30% | 37 (8.5) | 7 (5.5) | 30 (9.8) |  |
  ≥ 30% | 163 (37.6) | 57 (44.9) | 106 (34.5) |  |
Adjuvant CT | Â | Â | Â | 0.869 |
 No | 50 (11.5) | 16 (12.6) | 34 (11.1) |  |
 Anthracyclinec | 203 (46.3) | 58 (45.7) | 145 (47.2) |  |
 Taxaned | 9 (2.1) | 2 (1.6) | 7 (2.3) |  |
 Anthracycline + Taxanee | 172 (40.1) | 51 (40.1) | 121 (39.4) |  |
Adjuvant RT | Â | Â | Â | 1.000 |
 Yes | 81 (18.7) | 24 (18.9) | 57 (18.6) |  |
 No | 353 (81.3) | 103 (81.1) | 250 (81.4) |  |
Adjuvant ET | Â | Â | Â | 0.877 |
 Tamoxifen/Toremifene | 395 (91.0) | 115 (90.6) | 280 (91.2) |  |
 AIs | 15 (3.5) | 6 (4.7) | 9 (2.9) |  |
 Tamoxifen/AIs | 24 (5.5) | 6 (4.7) | 18 (5.9) |  |
Ovarian function suppression | Â | Â | Â | 1.000 |
 Yes | 14 (3.2) | 4 (3.1) | 10 (3.3) |  |
 No | 420 (96.8) | 123 (96.9) | 297 (96.7) |  |